Messenger RNA (mRNA) therapeutics developer Moderna (MRNA +11%) is up on over 40% higher volume following its Q2 report released this morning that included a pipeline update and an announcement that collaboration partner Vertex Pharmaceuticals (VRTX -1.4%) has extended their exclusive research partnership aimed at developing mRNA therapies for cystic fibrosis through Q1 2020 with options to extend further depending on progress.
Moderna will host its annual R&D Day in New York on September 12.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.